Analysts Set Option Care Health, Inc. (NASDAQ:OPCH) PT at $33.00

Shares of Option Care Health, Inc. (NASDAQ:OPCH) have been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $33.00.

A number of brokerages have recently weighed in on OPCH. JMP Securities reiterated a “market outperform” rating and issued a $30.00 price objective (down from $31.00) on shares of Option Care Health in a research report on Friday, January 10th. JPMorgan Chase & Co. lifted their price target on shares of Option Care Health from $40.00 to $41.00 and gave the company an “overweight” rating in a report on Thursday, March 6th. Barrington Research raised their target price on shares of Option Care Health from $33.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday, February 27th. Bank of America raised shares of Option Care Health from a “neutral” rating to a “buy” rating and lifted their target price for the company from $26.00 to $33.00 in a research note on Monday, January 13th. Finally, UBS Group started coverage on shares of Option Care Health in a research note on Thursday, December 5th. They issued a “neutral” rating and a $26.00 price target for the company.

Insiders Place Their Bets

In other news, insider Michael Bavaro sold 30,996 shares of the business’s stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $33.26, for a total value of $1,030,926.96. Following the sale, the insider now directly owns 44,974 shares of the company’s stock, valued at $1,495,835.24. The trade was a 40.80 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.64% of the company’s stock.

Hedge Funds Weigh In On Option Care Health

Large investors have recently modified their holdings of the stock. Mackenzie Financial Corp increased its stake in Option Care Health by 1.1% during the 4th quarter. Mackenzie Financial Corp now owns 49,579 shares of the company’s stock valued at $1,150,000 after purchasing an additional 556 shares in the last quarter. Peak Retirement Planning Inc. bought a new position in Option Care Health in the 4th quarter valued at approximately $1,026,000. Public Employees Retirement System of Ohio boosted its stake in Option Care Health by 21.6% during the 4th quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company’s stock valued at $43,000 after purchasing an additional 332 shares during the last quarter. PharVision Advisers LLC purchased a new stake in Option Care Health during the 4th quarter valued at $251,000. Finally, Voloridge Investment Management LLC bought a new stake in shares of Option Care Health in the 4th quarter worth $27,428,000. Hedge funds and other institutional investors own 98.05% of the company’s stock.

Option Care Health Stock Performance

Option Care Health stock opened at $33.42 on Friday. Option Care Health has a 1-year low of $21.39 and a 1-year high of $34.85. The firm has a market cap of $5.52 billion, a P/E ratio of 28.08, a P/E/G ratio of 2.30 and a beta of 1.33. The company has a current ratio of 1.73, a quick ratio of 1.32 and a debt-to-equity ratio of 0.77. The firm has a 50-day moving average of $30.25 and a 200-day moving average of $28.19.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.